Compare · DGX vs ILMN
DGX vs ILMN
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $21.57B, about the same size as DGX ($20.94B).
- Over the past year, DGX is up 7.1% and ILMN is up 86.8% - ILMN leads by 79.7 points.
- DGX has been more active in the news (14 items in the past 4 weeks vs 4 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Illumina Inc.
- Price
- $189.13-0.85%
- $142.59+2.53%
- Market cap
- $20.94B
- $21.57B
- 1M return
- -3.89%
- +12.76%
- 1Y return
- +7.09%
- +86.82%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 14
- 4
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest DGX
- Quest Diagnostics Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by Quest Diagnostics Incorporated
- Quest Diagnostics Prices $500 Million of Senior Notes
- Executive Vice President & CFO Samad Sam was granted 108 shares, increasing direct ownership by 0.32% to 33,376 units (SEC Form 4)
- SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.32% to 15,247 units (SEC Form 4)
- Director Gregg Vicky B was granted 68 shares, increasing direct ownership by 0.40% to 17,172 units (SEC Form 4)
- Director Carter Robert B increased direct ownership by 0.26% to 2,711 units (SEC Form 4)
- Director Lassiter Wright Iii increased direct ownership by 0.07% to 9,063 units (SEC Form 4)
- SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.29% to 13,490 units (SEC Form 4)
- SVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.31% to 11,901 units (SEC Form 4)
Latest ILMN
- Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits